Clinical risk factors for CNS engraftment
| Characteristic . | CNS+ (N = 23), n (%) . | CNS− (N = 6), n (%) . | P* . |
|---|---|---|---|
| Age, y | |||
| <10 | 17 (77) | 5 (23) | .631 |
| >10 | 6 (86) | 1 (14) | |
| Sex | |||
| Male | 10 (90) | 1 (10) | .228 |
| Female | 13 (70) | 5 (30) | |
| WCC | |||
| <100 | 15 (80) | 4 (20) | .947 |
| >100 | 8 (80) | 2 (20) | |
| CNS status | |||
| CNS-1 | 18 (80) | 6 (20) | .665 |
| CNS-3 | 2 (100) | 0 (0) | |
| TLP+ | 2 (100) | 0 (0) | |
| TLP− | 1 (100) | 0 (0) | |
| Cytogenetic risk | |||
| Low† | 6 (67) | 3 (33) | .455 |
| High‡ | 8 (80) | 2 (20) | |
| Other§ | 9 (90) | 1 (10) | |
| Outcome | |||
| CCR | 15 (70) | 6 (30) | .237 |
| Relapse | 7 (100) | 0 (0) | |
| TRM | 1 (100) | 0 (0) |
| Characteristic . | CNS+ (N = 23), n (%) . | CNS− (N = 6), n (%) . | P* . |
|---|---|---|---|
| Age, y | |||
| <10 | 17 (77) | 5 (23) | .631 |
| >10 | 6 (86) | 1 (14) | |
| Sex | |||
| Male | 10 (90) | 1 (10) | .228 |
| Female | 13 (70) | 5 (30) | |
| WCC | |||
| <100 | 15 (80) | 4 (20) | .947 |
| >100 | 8 (80) | 2 (20) | |
| CNS status | |||
| CNS-1 | 18 (80) | 6 (20) | .665 |
| CNS-3 | 2 (100) | 0 (0) | |
| TLP+ | 2 (100) | 0 (0) | |
| TLP− | 1 (100) | 0 (0) | |
| Cytogenetic risk | |||
| Low† | 6 (67) | 3 (33) | .455 |
| High‡ | 8 (80) | 2 (20) | |
| Other§ | 9 (90) | 1 (10) | |
| Outcome | |||
| CCR | 15 (70) | 6 (30) | .237 |
| Relapse | 7 (100) | 0 (0) | |
| TRM | 1 (100) | 0 (0) |
Clinical characteristics of patients whose samples infiltrated the CNS (CNS+) in the xenograft model, compared with those with no evidence of infiltration (CNS−). Cytogenetic high-risk group was defined according to the UKALL 2011 trial protocol.
CCR, continuous complete remission until last follow-up; TRM, treatment-related mortality.
Calculated using χ2 test.
t(12;21), High hyperdiploid.
t(9;22), iAMP21, t(17;19), 11q23.
t(7;9)dic(9;20), t(8;14) non-Burkitt, bcr-abl-like, immunoglobulin H translocation, CRLF2 deletion, no result.